U.S. markets open in 8 minutes

XBiotech Inc. (XBIT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.96+0.38 (+6.81%)
At close: 04:00PM EDT
6.25 +0.29 (+4.87%)
After hours: 05:20PM EDT

XBiotech Inc.

5217 Winnebago Lane
Austin, TX 78744
United States
512 386 2900

Full Time Employees97

Key Executives

NameTitlePayExercisedYear Born
Mr. John SimardFounder, Pres, CEO & Chairman3.42MN/A1962
Ms. Queena Han CPA, B.A., CPA, C.G.A.VP of Fin. & HR and Sec.358.25kN/A1967
Dr. Sushma ShivaswamyChief Scientific Officer456.24kN/A1978
Mr. Benjamín GuzmánSr. VP of Corp. Strategy & Fin.N/AN/A1956
Ms. Lisa SimardDirector of Corp. Strategy - XBiotech USA, Inc.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Corporate Governance

XBiotech Inc.’s ISS Governance QualityScore as of May 1, 2022 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.